Case report: The role and value of radiotherapy in treatment of inflammatory myofibroblastic tumor

Haiwei Guo; Mingyun Jiang; Juanjuan Cai; Ruiqi Liu; Weiping Yao; Xiaodong Liang; Haibo Zhang

doi:10.3389/fonc.2024.1395787

Case report: The role and value of radiotherapy in treatment of inflammatory myofibroblastic tumor

Front Oncol. 2024 Nov 15:14:1395787. doi: 10.3389/fonc.2024.1395787. eCollection 2024.

Authors

Haiwei Guo^#^{1

2

3}, Mingyun Jiang^#⁴, Juanjuan Cai⁵, Ruiqi Liu⁶, Weiping Yao⁶, Xiaodong Liang⁶, Haibo Zhang⁶

Affiliations

¹ Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People' s Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
² Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, China.
³ Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, China.
⁴ Department of Oncology, Taixing People's Hospital, Taixing, China.
⁵ Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
⁶ Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.

^# Contributed equally.

Abstract

Background: Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue neoplasms. Accordingly, there is no standardized therapy for unresectable or advanced IMT. Chemotherapy, radiotherapy, and targeted molecular therapy play an important role in unresectable or advanced IMT.

Case presentation: We present a 54-year-old man with a cough and chest distress case report. The thoracic surgeon performed the right upper pulmonary occupying lesion wedge resection and enlarged lymph node excision biopsy. Pathologic diagnosis revealed that the morphology of "right upper lung mass" was considered as Inflammatory Myofibroblastic Tumor (IMT). Radiotherapy was indicated at a high dose: 5400cGy in 27 fractions of 2Gy over 5 weeks were delivered combined with cisplatin. The patient was given a CT/MRI and hematological index every 3 months and experienced no more adverse events. The patient survives with no tumor recurrence as of the last follow-up. Progression-free survival (PFS) exceeded 5 years.

Conclusions: We have reviewed the literature and summarized and discussed the radiotherapy treatment options and challenges for IMT. We first reported high-dose radiotherapy combined with chemotherapy treatment for unresectable IMT. Concurrent radiochemotherapy may be considered an intensive treatment for local progress, local recurrence, and nonresectable IMT patients.

Keywords: case report; concurrent radiochemotherapy; inflammatory myofibroblastic tumor; radiation dose; radiotherapy.

Publication types

Case Reports

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported in part by grants from the National Natural Science Foundation of China (Grant number: 82473238 to HZ).